Episode
AstraZeneca Stock: Beat, Raised, Near 52-Week Lows — So Why We Say HOLD (H1 2026)
- Published
- Jul 27, 2026
- Duration seconds
- 813
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/astrazeneca-stock-beat-raised-near-52-week-lows-so-why-we-say-hold-h1-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/astrazeneca-stock-beat-raised-near-52-week-lows-so-why-we-say-hold-h1-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
AstraZeneca (AZN) H1 2026 — AstraZeneca (AZN), the UK-based global pharma giant and world leader in oncology, reported H1 & Q2 2026 this morning (period ended June 30, 2026): first-half revenue rose 9% (+6% CER) to a record $30,672M and core EPS jumped 12% to $5.21, with core operating profit up 11%. Q2 accelerated — revenue +6% to $15,384M and core EPS +21% to $2.63 on margin expansion and a lower tax rate. Oncology led, up 18% to $14,124M (46% of revenue); Rare Disease rose 13% to ~$4.9B and Respiratory & Immunology ~9%, more than offsetting an 8% decline in CVRM from Farxiga's US loss of exclusivity and China volume-based procurement. Management RAISED the interim dividend to $1.06, logged ~30 approvals since Q4 2025, flagged 20+ high-value readouts in the next 18 months, and REAFFIRMED FY2026 guidance (revenue mid-to-high single-digit % CER, core EPS low-double-digit % CER, tax 18-22%) plus the $80B-by-2030 revenue ambition. Yet the ADR (~$169) sits near a 52-week low, ~20% below its $213 high. On an owner-earnings DCF — even leaning to the ambition path — our fair value lands near $160/ADR, modestly BELOW the price: a world-class franchise priced for a lot to go right. Our call: HOLD, 3/5. Wall Street rates it Buy (20 buy / 15 hold / 6 sell, 41 analysts; ~$187 avg target, +10%), so we're aligned on the business but a touch more cautious on value. AstraZeneca (AZN) is Britain's biggest drugmaker and the world's leading oncology company, a ~$260B biopharma giant with one of the deepest late-stage pipelines in the industry. H1 2026 (reported July 27, 2026) was a clean beat-and-raise: revenue up 9% to a record $30.7B (+6% CER), core EPS up 12% to $5.21, and core operating profit up 11%; Q2 core EPS jumped 21% to $2.63. Oncology is now the engine — up 18% to $1…